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Smoker’s Paradox in Patients With ST-Segment Elevation Myocardial
Infarction Undergoing Primary Percutaneous Coronary Intervention
Tanush Gupta, MD; Dhaval Kolte, MD, PhD; Sahil Khera, MD; Prakash Harikrishnan, MD; Marjan Mujib, MD, MPH; Wilbert S. Aronow, MD;
Diwakar Jain, MD; Ali Ahmed, MD, MPH; Howard A. Cooper, MD; William H. Frishman, MD; Deepak L. Bhatt, MD, MPH;
Gregg C. Fonarow, MD; Julio A. Panza, MD
Background-—Prior studies have found that smokers undergoing thrombolytic therapy for ST-segment elevation myocardial
infarction have lower in-hospital mortality than nonsmokers, a phenomenon called the “smoker’s paradox.” Evidence, however, has
been conflicting regarding whether this paradoxical association persists in the era of primary percutaneous coronary intervention.
Methods and Results-—We used the 2003–2012 National Inpatient Sample databases to identify all patients aged ≥18 years who
underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Multivariable logistic
regression was used to compare in-hospital mortality between smokers (current and former) and nonsmokers. Of the 985 174
patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, 438 954
(44.6%) were smokers. Smokers were younger, were more often men, and were less likely to have traditional vascular risk factors
than nonsmokers. Smokers had lower observed in-hospital mortality compared with nonsmokers (2.0% versus 5.9%; unadjusted
odds ratio 0.32, 95% CI 0.31–0.33, P<0.001). Although the association between smoking and lower in-hospital mortality was partly
attenuated after baseline risk adjustment, a significant residual association remained (adjusted odds ratio 0.60, 95% CI 0.58–0.62,
P<0.001). This association largely persisted in age-stratified analyses. Smoking status was also associated with shorter average
length of stay (3.5 versus 4.5 days, P<0.001) and lower incidence of postprocedure hemorrhage (4.2% versus 6.1%; adjusted odds
ratio 0.81, 95% CI 0.80–0.83, P<0.001) and in-hospital cardiac arrest (1.3% versus 2.1%; adjusted OR 0.78, 95% CI 0.76–0.81,
P<0.001).
Conclusions-—In this nationwide cohort of patients undergoing primary percutaneous coronary intervention for ST-segment
elevation myocardial infarction, we observed significantly lower risk-adjusted in-hospital mortality in smokers, suggesting that the
smoker’s paradox also applies to ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary
intervention. ( J Am Heart Assoc. 2016;5:e003370 doi: 10.1161/JAHA.116.003370)
Key Words: primary percutaneous coronary intervention • smoker’s paradox • smoking • ST-segment elevation myocardial
infarction
C igarette smoking is the leading preventable cause ofpremature death in the United States. Approximately
one-third of all coronary artery disease (CAD) deaths in the
United States annually are attributable to smoking.1 Some
prior studies, however, have suggested the existence of a
“smoker’s paradox,” implying that the outcomes of acute
myocardial infarction (MI) may be more favorable in smokers
than in nonsmokers.2–6 More recently, smoking has also been
shown to be associated with lower in-hospital mortality in
patients with acute ischemic stroke, acute heart failure, and
cardiac arrest.7–10
This phenomenon of smoker’s paradox was first introduced
into scientific discourse >25 years ago, when studies in the
prethrombolytic era showed that smokers with acute MI
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experienced lower mortality compared with nonsmokers.3–5,11
Similar findings of paradoxical associations with smoking
were also seen subsequently in randomized clinical trials
investigating thrombolytic therapy for ST-segment elevation
MI (STEMI).2,12,13 These paradoxically lower mortality rates
were largely attributed to a cumulative effect of younger age,
fewer comorbidities, lesser extent of CAD, and more aggres-
sive treatment of acute MI in smokers. Alternatively, patho-
physiological differences between smokers and nonsmokers
with acute MI have also been postulated as a basis for this
paradox, including a greater thrombus burden in smokers,
leading to greater efficacy of thrombolytic therapy,14–16 and
greater responsiveness to antiplatelet therapies.17–20
Whether a true biochemical basis exists for the smoker’s
paradox remains inconclusive.
The majority of STEMI patients in current practice are
treated with primary percutaneous coronary intervention
(pPCI); however, studies of STEMI patients undergoing pPCI
have found conflicting evidence regarding whether the
smoker’s paradox exists in this population.21–24 We sought
to determine the association of smoking status with in-
hospital outcomes in STEMI patients undergoing pPCI, using




Data were obtained from the 2003–2012 NIS databases. The
NIS is the largest publicly available all-payer database of
hospitalized patients in the United States and is sponsored by
the US Agency for Healthcare Research and Quality as a part
of the Healthcare Cost and Utilization Project (HCUP).25 The
NIS includes deidentified patient data on demographics,
admission diagnosis, comorbidities, procedures, and out-
comes from all nonfederal, short-term, general, and other
specialty acute care hospitals in the United States. Patients
admitted under observation status or those admitted to
psychiatric or rehabilitation hospitals, long-term care facilities,
and chemical dependence units are not included. The
database is composed of a random 20% sample of all
hospitalized patients from participating states (44 states in
2012) in a given year. During 2003–2011, the NIS was
constructed using data from all inpatient discharges (100%)
from a random 20% sample of all reporting hospitals (stratified
by hospital ownership, patient volume, urban or rural location,
teaching status, and geographic region). In 2012, the
database was redesigned to include data from a 20% sample
of discharges from all participating hospitals (100%). The new
design of the NIS delivers more precise and stable weighted
estimates and reduces the margin of error.26 To account for
these changes in the sampling methodology, a new set of
weights called “trend weights” were provided from 2012 data
and for data from the previous years to allow the use of 2012
data along with the previous years’ data.27
The New York Medical College institutional review board
deemed this study exempt because the HCUP-NIS is a publicly
available database containing deidentified patient information.
Study Population
We used the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnosis codes
410.01 to 410.61, 410.81, and 410.91 to identify all patients
aged ≥18 years with the primary diagnosis of STEMI. We
chose the primary diagnosis because it is considered the
principal reason for hospital admission. Patients who under-
went thrombolysis (ICD-9-CM codes 99.19, V45.88) were
excluded. STEMI patients undergoing pPCI were recognized as
those who underwent PCI (ICD-9-CM codes 00.66, 36.01,
36.05, 36.06, 37.07) on the day of hospital admission and
constituted our final study cohort (n=958 174).28 Smokers
(both current and former) were then identified using ICD-9-CM
code 305.1 or V15.82 (n=438 954). Patients who did not
have either of these diagnosis codes were considered
nonsmokers (n=546 220). Prior studies have indicated that
these codes have sensitivity of 100%, specificity of 32%, and
accuracy of 66% to identify smokers in administrative
databases, with little evidence of documentation bias.29
Outcomes Measures
Our primary outcome of interest was all-cause in-hospital
mortality defined as “died” in the NIS database. We used
average length of stay, postprocedure hemorrhage, and
incidence of in-hospital cardiac arrest as secondary out-
comes. The ICD-9-CM codes used to identify these conditions
are provided in Table 1.
Patient and Hospital Characteristics
Baseline patient characteristics used included demographics
(age, sex, race, primary expected payer, median household
income for patient ZIP code, weekday versus weekend
admission), all comorbidities from the Elixhauser Comorbidity
Index (acquired immune deficiency syndrome, alcohol abuse,
deficiency anemia, rheumatoid arthritis/collagen vascular
diseases, chronic blood loss anemia, congestive heart failure,
chronic pulmonary disease, coagulopathy, depression, dia-
betes [uncomplicated], diabetes with chronic complications,
drug abuse, hypertension, hypothyroidism, chronic renal
failure, liver disease, lymphoma, fluid and electrolyte disor-
ders, metastatic cancer, other neurological disorders, obesity,
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paralysis, peripheral vascular disease, psychosis, pulmonary
circulation disorders, solid tumor without metastasis, valvular
disease, and weight loss),30,31 and other clinically relevant
comorbidities (dyslipidemia, known CAD, family history of
CAD, prior MI, prior PCI, prior coronary artery bypass grafting,
atrial fibrillation, carotid artery disease, and dementia). A
combination of ICD-9-CM codes and HCUP Clinical Classifi-
cation Software codes were used to identify baseline
characteristics (Table 1). Hospital-level variables such as
census region (Northeast, Midwest, South, and West), location
(rural or urban), bed size (small, medium, or large), and
teaching status were also included.
Statistical Analysis
Weighted estimates were obtained by applying trend weights
to the unweighted discharge data. We initially compared
patient demographics, hospital characteristics, and comor-
bidities between smokers and nonsmokers using the Pearson
chi-square test for categorical variables and the Student t test
for continuous variables to identify significant univariate
associations. Multivariable logistic regression was used to
compare in-hospital outcomes (in-hospital mortality, postpro-
cedure hemorrhage, incidence of in-hospital cardiac arrest)
between smokers and nonsmokers undergoing pPCI for
STEMI. Variables included in the regression model were
baseline demographics, hospital characteristics, comorbid
conditions, and STEMI location (anterior, inferior, or other).
Race and ethnicity data were missing for 14.6% of the study
population and thus were not included in the regression
model. We also compared in-hospital mortality separately
between current smokers and nonsmokers and between
former smokers and nonsmokers to assess whether there was
any heterogeneity in the association of smoking status with
in-hospital mortality when these groups were studied sepa-
rately. Average length of stay was compared for smokers and
nonsmokers using linear regression models. Given the
positively skewed distribution, log transformation of length
of stay was used as the dependent variable. To study whether
the association of smoking with in-hospital mortality in the
study cohort differed by age, we performed the multivariable
analysis in different age strata (ie, <40, 40–49, 50–59, 60–69,
70–79, 80–89, and ≥90 years). We also repeated the
multivariable analysis in subgroups stratified by admission
year to assess whether the association of smoking with in-
hospital mortality persisted equally throughout the study
period. To explore whether the difference in in-hospital
mortality between smokers and nonsmokers with STEMI in
our study was driven by differences in baseline characteristics
between hospitalized smokers and nonsmokers in general, we
analyzed the association of smoking with risk-adjusted in-
hospital mortality in patients hospitalized with hip fractures
(ICD-9-CM codes 820.0x, 820.1x, 820.2x, 830.3x, 820.8, and
820.9) or with severe sepsis (ICD-9-CM code 995.92) during
the same time period using the same multivariable regression
models.
Statistical analysis was performed using IBM SPSS Statis-
tics 21.0 (IBM Corp). A 2-sided P value of <0.05 was used to
assess for statistical significance for all analyses. Categorical
variables are expressed as percentages and continuous
variables as meanSD. Odds ratio (OR) and 95% CIs were
used to report the results of logistic regression.
Results
Baseline Characteristics
From 2003 to 2012, of the 985 174 STEMI patients aged
≥18 years who underwent pPCI, 438 954 (44.6%) were
smokers (either current or former). Smokers were, on
average, 8 years younger than nonsmokers (mean age
56.6 versus 64.3 years; P<0.001) and more likely to be white
men. Smokers were less likely to have atrial fibrillation,
congestive heart failure, diabetes mellitus, hypertension, or
chronic renal failure but more often had known CAD, history
of prior MI, dyslipidemia, alcohol abuse, drug abuse, and
chronic pulmonary disease (P<0.001 for all comparisons).
Smokers were less likely to have anterior wall STEMI and
more likely to have inferior wall STEMI (P<0.001) (Table 2).





Known CAD ICD-9-CM 414.00–414.07
Family history of CAD ICD-9-CM V17.3
Prior myocardial infarction ICD-9-CM 412




Atrial fibrillation ICD-9-CM 427.31
Carotid artery disease ICD-9-CM 433.10




Postprocedure hemorrhage ICD-9-CM 998.11, 998.12, 285.1
In-hospital cardiac arrest ICD-9-CM 99.60, 99.63
CAD indicates coronary artery disease; CCS, Clinical Classification Software; ICD-9-CM,
International Classification of Diseases, Ninth Revision, Clinical Modification; PCI,
percutaneous coronary intervention.
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Table 2. Baseline Demographics, Hospital Characteristics,
and Comorbidities of Patients Aged ≥18 Years With STEMI





% (n=438 954) P Value
Age, meanSD (years) 64.313.2 56.611.3 <0.001





Asian or Pacific Islander 2.5 1.5
Native American 0.5 0.4
Other 4.0 3.4
Primary expected payer <0.001
Medicare 45.6 25.5
Medicaid 4.8 8.1
Private insurance 39.7 47.1
Self-pay 6.2 13.1
No charge 0.5 1.3
Other 3.2 4.8






Urban location 94.3 94.1 <0.001






































Carotid artery disease 0.5 0.5 0.93
Dementia 1.1 0.3 <0.001




Alcohol abuse 1.4 4.9 <0.001














Coagulopathy 3.4 2.0 <0.001







Drug abuse 1.0 3.4 <0.001
Hypertension 59.2 54.8 <0.001
Hypothyroidism 7.0 4.2 <0.001
Liver disease 0.6 0.8 <0.001








Obesity 9.9 11.8 <0.001
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In-Hospital Outcomes of Smokers and
Nonsmokers With STEMI Undergoing pPCI
In the overall cohort of STEMI patients undergoing pPCI,
smoking was associated with lower in-hospital mortality (2.0%
versus 5.9%; unadjusted OR 0.32, 95% CI 0.31–0.33,
P<0.001). This unadjusted mortality difference was attenu-
ated substantially but remained significant after risk adjust-
ment for demographics, hospital characteristics, baseline
comorbidities, and STEMI location (adjusted OR 0.60, 95%
CI 0.58–0.62, P<0.001) (Table 3). When further adjusted
for secondary outcomes (in-hospital cardiac arrest, postpro-
cedure hemorrhage), there was no significant change in the
association of smoking with in-hospital mortality (adjusted OR
0.61, 95% CI 0.57–0.64, P<0.001). Although there were slight
year-to-year variations (Pinteraction<0.001), the association
between smoking and lower risk-adjusted in-hospital mortality
persisted throughout the study period in subgroups stratified
by admission year (Table 4).
When in-hospital mortality was compared separately for
current smokers versus nonsmokers (1.7% versus 5.9%;
unadjusted OR 0.28, 95% CI 0.26–0.29, P<0.001; adjusted
OR 0.56, 95% CI 0.52–0.60, P<0.001) and for former smokers
versus nonsmokers (2.9% versus 5.9%; unadjusted OR 0.48,
95% CI 0.44–0.52, P<0.001; adjusted OR 0.70, 95% CI 0.64–
0.76, P<0.001), smoking status was associated with lower
risk-adjusted in-hospital mortality in both comparisons,
although this association was stronger in current smokers
than in former smokers.
Smoking was also associated with shorter average length of
stay (3.5 versus 4.5 days; P<0.001) and lower incidence of
postprocedure hemorrhage (4.2% versus 6.1%; unadjusted OR
0.67, 95% CI 0.66–0.69, P<0.001; adjusted OR 0.81, 95% CI
0.80–0.83, P<0.001) and in-hospital cardiac arrest (1.3% versus
2.1%; unadjusted OR 0.60, 95% CI 0.58–0.62, P<0.001;
adjusted OR 0.78, 95% CI 0.76–0.81, P<0.001) (Table 3).
Age-Stratified Analysis
To assess whether the younger age of smokers was
influencing the association with lower in-hospital mortality,
we performed an age-stratified analysis (Pinteraction<0.001). As
expected, the proportion of smokers decreased with increas-
ing age, whereas in-hospital mortality increased (Table 5).
Mortality differences between smokers and nonsmokers






% (n=438 954) P Value











Valvular disease 0.1 <0.1 <0.001
Weight loss 1.1 0.6 <0.001
STEMI location <0.001
Anterior STEMI 38.3 33.1
Inferior STEMI 50.1 57.2
Other STEMI 11.6 9.7
STEMI indicates ST-segment elevation myocardial infarction.
*Bed size categories are specific for hospital location and teaching status.
†Comorbidities (including the 29 comorbidities from the Elixhauser Comorbidity Index)
were extracted from the database using the International Classification of Diseases,
Ninth Revision, Clinical Modification diagnosis or Clinical Classification Software codes.
Table 3. In-Hospital Outcomes in Nonsmokers and Smokers With STEMI Undergoing Primary Percutaneous Coronary Intervention
Outcome Nonsmokers (n=546 220) Smokers (n=438 954)
Odds Ratio (95% CI)
P Value†Unadjusted Adjusted*
In-hospital mortality 32 321 (5.9%) 8646 (2.0%) 0.32 (0.31–0.33) 0.60 (0.58–0.62) <0.001
Secondary outcomes
Postprocedure hemorrhage 33 051 (6.1%) 18 246 (4.2%) 0.67 (0.66–0.69) 0.81 (0.80–0.83) <0.001
In-hospital cardiac arrest 11 710 (2.1%) 5658 (1.3%) 0.60 (0.58–0.62) 0.78 (0.76–0.81) <0.001
Average length of stay 4.55.5 days 3.53.0 days — — <0.001
Rates of in-hospital mortality, postprocedure hemorrhage, and in-hospital cardiac arrest are depicted as n (%) and average length of stay as meanSD. STEMI indicates ST-segment
elevation myocardial infarction.
*Adjusted for age, sex, primary payer status, weekend admission, median household income for patient ZIP code, hospital characteristics (bed size, region, location, teaching status), all
Elixhauser comorbidities, other clinically relevant comorbidities (known coronary artery disease, carotid artery disease, atrial fibrillation, dementia, dyslipidemia, family history of coronary
artery disease, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary bypass surgery), and STEMI location.
†P values reported for adjusted comparisons.
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increasing age; the adjusted OR for association of smoking
with mortality increased from 0.37 in patients aged <40 years
to 0.77 in those aged 80 to 89 years. Moreover, the
association of smoking with lower in-hospital mortality was
no longer significant in patients ≥90 years of age.
In-Hospital Mortality in Smokers and
Nonsmokers With Hip Fractures or Severe Sepsis
To explore whether the paradoxically lower risk-adjusted in-
hospital mortality in smokers with STEMI in our study was
driven by differences in baseline demographics and comor-
bidities between hospitalized smokers and nonsmokers in
general, we analyzed the association of smoking status with
in-hospital mortality in 2 conditions in which this association
has not been previously studied—hip fractures and severe
sepsis—using the same regression models. Of the 3 048 272
patients hospitalized with hip fractures from 2003 to 2012,
14.5% were smokers and 85.5% were nonsmokers (mean age
72.5 versus 80.2 years; P<0.001). Smoking was associated
with lower risk-adjusted in-hospital mortality after multivari-
able adjustment (1.6% versus 2.8%; unadjusted OR 0.57, 95%
Table 4. In-Hospital Mortality by Admission Year for Nonsmokers and Smokers With STEMI Undergoing Primary Percutaneous
Coronary Intervention
Year
In-Hospital Mortality, % Odds Ratio (95% CI)
P Value†Nonsmokers Smokers Unadjusted Adjusted*
2003 4.9 1.4 0.27 (0.24–0.30) 0.65 (0.58–0.73) <0.001
2004 5.4 1.1 0.19 (0.17–0.22) 0.42 (0.37–0.48) <0.001
2005 5.8 1.3 0.21 (0.19–0.23) 0.44 (0.40–0.50) <0.001
2006 5.6 1.4 0.24 (0.22–0.26) 0.51 (0.46–0.56) <0.001
2007 6.2 1.6 0.25 (0.23–0.27) 0.48 (0.43–0.53) <0.001
2008 6.5 1.8 0.26 (0.24–0.28) 0.50 (0.46–0.55) <0.001
2009 6.0 2.2 0.36 (0.33–0.38) 0.64 (0.59–0.69) <0.001
2010 6.0 2.2 0.36 (0.34–0.39) 0.59 (0.55–0.64) <0.001
2011 6.3 2.8 0.43 (0.40–0.45) 0.69 (0.64–0.74) <0.001
2012 6.3 2.9 0.44 (0.42–0.47) 0.66 (0.62–0.71) <0.001
Pinteraction<0.001 for smoking and year. STEMI indicates ST-segment elevation myocardial infarction.
*Adjusted for age, sex, primary payer status, weekend admission, median household income for patient ZIP code, hospital characteristics (bed size, region, location, teaching status), all
Elixhauser comorbidities, other clinically relevant comorbidities (known coronary artery disease, carotid artery disease, atrial fibrillation, dementia, dyslipidemia, family history of coronary
artery disease, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary bypass surgery), and STEMI location.
†P values reported for adjusted comparisons.
Table 5. In-Hospital Mortality by Age for Nonsmokers and Smokers With STEMI Undergoing Primary Percutaneous Coronary
Intervention
Age, y n Smoker, %
In-Hospital Mortality, % Odds Ratio (95% CI)
P Value†Nonsmokers Smokers Unadjusted Adjusted*
<40 36 445 62.2 2.8 0.7 0.26 (0.21–0.31) 0.37 (0.30–0.46) <0.001
40–49 158 936 61.7 2.6 0.8 0.32 (0.30–0.35) 0.44 (0.40–0.48) <0.001
50–59 289 200 54.1 3.2 1.4 0.42 (0.40–0.44) 0.56 (0.53–0.59) <0.001
60–69 245 830 42.2 4.9 2.4 0.47 (0.45–0.50) 0.59 (0.56–0.62) <0.001
70–79 159 348 27.3 7.7 4.2 0.53 (0.50–0.56) 0.69 (0.66–0.73) <0.001
80–89 85 031 16.0 12.3 7.8 0.61 (0.57–0.65) 0.77 (0.71–0.83) <0.001
≥90 10 384 9.1 16.3 16.9 1.05 (0.88–1.25) 1.18 (0.97–1.44) 0.10
Pinteraction<0.001 for smoking and age. STEMI indicates ST-segment elevation myocardial infarction.
*Adjusted for sex, primary payer status, weekend admission, median household income for patient ZIP code, hospital characteristics (bed size, region, location, teaching status), all
Elixhauser comorbidities, other clinically relevant comorbidities (known coronary artery disease, carotid artery disease, atrial fibrillation, dementia, dyslipidemia, family history of coronary
artery disease, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary bypass surgery), and STEMI location.
†P values reported for adjusted comparisons.
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CI 0.56–0.59, P<0.001; adjusted OR 0.70, 95% CI 0.69–0.72,
P<0.001). During the same time period, 3 773 654 patients
were hospitalized with sepsis. Of these, 12.4% were smokers.
Smokers were younger (63.2 versus 67.4 years; P<0.001)
and had lower risk-adjusted morality than nonsmokers (26.7%
versus 33.8%; unadjusted OR 0.72, 95% CI 0.71–0.72,
P<0.001; adjusted OR 0.82, 95% CI 0.81–0.83, P<0.001).
Discussion
Our analysis of a large real-world nationwide cohort of
100 000 STEMI patients undergoing pPCI showed that
smokers had lower in-hospital mortality, shorter average
length of stay, and lower incidence of postprocedure hemor-
rhage and in-hospital cardiac arrest than nonsmokers. Even
after adjustment for baseline covariates, the adjusted odds of
in-hospital mortality were significantly lower in nonsmokers.
We also found that the association of smoking with lower risk-
adjusted in-hospital mortality differed across age strata, with
this paradoxical association being stronger in younger versus
older age groups.
Cigarette smoking is an established risk factor for
atherosclerotic cardiovascular disease.1,32 Consistent with
this, smokers presenting with STEMI in our study were
8 years younger and were less likely to have vascular risk
factors than nonsmokers, providing direct evidence for the
deleterious effects of cigarette smoking. Despite risk adjust-
ment for these baseline differences, the association of
smoking with lower in-hospital mortality persisted. A novel
aspect of our study was the additional assessment for
potential confounding by examining the association with
smoking with in-hospital mortality in patients hospitalized
with hip fractures and severe sepsis. We found that smokers
had lower risk-adjusted in-hospital mortality than nonsmokers
in both these populations. Smokers were 8 years younger
than nonsmokers among patients with hip fractures, whereas
the mean age difference between smokers and nonsmokers
was 4 years in the sepsis cohort. Interestingly, this
translated into a greater beneficial association of smoking
with in-hospital mortality in patients hospitalized with hip
fractures (adjusted OR 0.70) compared with patients with
severe sepsis (adjusted OR 0.82). These findings suggest that
the lower risk-adjusted in-hospital mortality in hospitalized
smokers was driven in part by residual confounding due to
inadequate adjustment for the biological effects of age. It is
probable that the lower in-hospital mortality after extensive
multivariable risk adjustment in smokers with STEMI in our
study also represents continued unmeasured confounding;
however, given that the favorable association of smoking with
in-hospital mortality after risk adjustment was greater in
STEMI patients than in patients with either hip fractures or
sepsis, it is possible that underlying biological differences in
pathophysiology and response to treatment in smokers
versus nonsmokers with STEMI also account, at least in part,
for this paradoxical association.
Multiple randomized trials with thrombolytic therapy have
reported lower short- and long-term mortality in smokers with
STEMI.12,14,33–35 Although in most12,34 of these studies, the
association between smoking and reduced mortality was no
longer significant after baseline risk adjustment, some2
showed persistent reduced mortality in smokers, even after
correction for baseline differences between smokers and
nonsmokers. The hypothesized mechanism for superior
response of smokers to thrombolytic therapy is that smoking
does not affect atherosclerotic plaque vulnerability as much
as it increases hypercoagulability. Smoking has been directly
associated with a procoagulant state with effects on
endothelial dysfunction, increased platelet activation and
aggregation, increased circulating levels of fibrinogen, and
increased thrombin generation.36,37 Components of cigarette
smoke have also been shown to impair fibrin crosslinking.38
These findings support the hypothesis that the pathogenesis
of STEMI in smokers may be predominantly thrombogenic and
less likely atherogenic, making it more amenable to throm-
bolytic therapy. Studies have shown that smokers with STEMI
have better epicardial flow after thrombolytic therapy34 and
improved myocardial perfusion demonstrated by Thromboly-
sis in Myocardial Infarction perfusion grade.39
Data on the association of smoking with in-hospital
outcomes in STEMI patients undergoing pPCI are more
limited. In the Controlled Abciximab and Device Investigation
to Lower Late Angioplasty Complications (CADILLAC) trial,
patients with STEMI were randomized to angioplasty with or
without abciximab versus stenting with or without abciximab.
Smokers had significantly lower mortality than nonsmokers
both at 30 days and 1 year; however, smoking was no longer
associated with lower 1-year mortality after baseline risk
adjustment.21 A recent single-center retrospective study of
382 STEMI patients presenting for pPCI via field triage
showed that current smoking was not predictive of 30-day all-
cause mortality or major adverse cardiac events after
multivariable risk adjustment; however, given the small
sample size and low event rate, the study was underpowered
to assess the validity of the smoker’s paradox in this patient
population.24 Of note, Zhang et al40 recently reported the
association of smoking with 5-year outcomes of 1800
patients in the Synergy Between PCI With Taxus and Cardiac
Surgery (SYNTAX) trial. Although smoking status was found to
be an independent predictor of the primary composite end
point of death, MI, and stroke after multivariable risk
adjustment, this association was driven by the effect of
smoking on subsequent MI, and no statistically significant
association with mortality was observed at 5-year follow-up.
More important, the SYNTAX trial examined a population of
DOI: 10.1161/JAHA.116.003370 Journal of the American Heart Association 7























patients with predominantly stable CAD; therefore, these
findings cannot be compared directly with the MI population,
in which the smoker’s paradox has been classically described.
Ours is the largest study to date to investigate the association
of smoking with in-hospital outcomes in the pPCI era. In
addition, given the large sample size, our study was
sufficiently powered to allow for multivariable analysis across
all age strata. We observed that the mortality difference
between smokers and nonsmokers diminished substantially
with increasing age and was no longer significant in nonage-
narians with STEMI. These data suggest that the overall
association of smoking with lower in-hospital mortality is
driven mostly by younger age groups.
A possible biological mechanism to explain the existence
of this paradox in the pPCI population could be the increased
responsiveness of smokers to antiplatelet therapies, partic-
ularly clopidogrel, which is still the predominant P2Y12
inhibitor in current practice. In the Clopidogrel and Adjunctive
Reperfusion Therapy-Thrombolysis in Myocardial Infarction
(CLARITY-TIMI 28) trial, although clopidogrel reduced the rate
of the primary end point of a closed infarct–related artery or
death and MI before angiography in the entire study
population, the benefit was especially marked among patients
who smoked ≥10 cigarettes per day versus those who did
not.41 Similarly, in the Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization, Management, and Avoidance
(CHARISMA) trial, among the 12 152 participants with
established cardiovascular disease, clopidogrel reduced all-
cause and cardiovascular mortality at 28 months in current
smokers but not in nonsmokers.18 Similar findings of effect
modification of clopidogrel activity by smoking status have
been reported in other studies.17 Pharmacokinetic and
pharmacodynamics studies have shown that smokers have
greater inhibition of platelet aggregation, lower P2Y12 reaction
units, and lower odds of high platelet reactivity while on
clopidogrel compared with nonsmokers.19 A proposed mech-
anism to explain the differential effect of clopidogrel in
smokers versus nonsmokers is the induction of cytochrome
P450 1A2 and 2B6 enzymes by cigarette smoking, both of
which are involved in the hepatic biotransformation of
clopidogrel to its active metabolite.42 There is also some
evidence that smoking status potentiates prasugrel activity. A
platelet-function substudy of the Targeted Platelet Inhibition
to Clarify the Optimal Strategy to Medically Manage Acute
Coronary Syndromes (TRILOGY-ACS) trial, which randomized
medically managed ACS patients to prasugrel versus clopi-
dogrel, showed that persistent smokers had lower P2Y12
reaction unit values at 6 months in both treatment groups
compared with nonsmokers. Nicotine has been shown to be
associated with higher P2Y12 receptor expression in human
platelet lysates; it is possible that the increased density of
P2Y12 receptors on the platelet surface in both clopidogrel-
and prasugrel-treated smokers versus nonsmokers could play
a role in the observed effect of smoking on platelet
inhibition.43 In addition, among smokers, the risk of ischemic
outcomes was significantly reduced with prasugrel versus
clopidogrel.20 The greater efficacy of prasugrel versus clopi-
dogrel in smokers might be explained, theoretically, by the
association of the reported increased density of P2Y12
receptors among smokers with a greater risk of ischemic
events that is possibly diminished to a greater degree with a
more potent P2Y12 inhibitor such as prasugrel. A subanalysis
of the Harmonizing Outcomes with Revascularization and
Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial
also showed that in patients undergoing pPCI for STEMI,
bivalirudin monotherapy was associated with lower 30-day
and 1-year mortality compared with unfractionated heparin
plus glycoprotein IIb/IIIa inhibitors in smokers but not in
nonsmokers.44 These data on the differential clinical efficacy
of clopidogrel, prasugrel, and bivalirudin in smokers versus
nonsmokers could be a possible mechanistic explanation for
the association of smoking with lower in-hospital mortality in
patients undergoing pPCI for STEMI.
This apparent smoker’s paradox should not be viewed as
an endorsement or inadvertent benefit of cigarette smoking.
Ample evidence shows the harmful nature of smoking, and
these modest differences in in-hospital outcomes would likely
be offset by the long-term mortality attributable to cigarette
smoking. Intensive efforts to encourage smoking cessation as
a public health measure to reduce cardiovascular disease
should remain an important goal.45
Study Limitations
Our present analysis of the association of smoking with in-
hospital outcomes in STEMI patients undergoing pPCI has
several limitations. It is possible that smokers with STEMI had
higher mortality rates before presentation to the hospital than
nonsmokers, with those being hospitalized already represent-
ing the “survivors.” Given the lack of information on out-of-
hospital deaths, we were unable to ascertain whether this bias
was present in our study cohort. Because of the unavailability
of patient charts and medical records, cumulative smoking
exposure in terms of number of pack-years could not be
quantified, and we were unable to study the association of
amount of smoking with outcomes. We were also unable to
determine the time of smoking cessation for former smokers.
Given the abstracted nature of the data set, we were unable
to assess the duration or severity of comorbid conditions. As
an administrative database, the accuracy of NIS data depends
greatly on the training and expertise of the coders; therefore,
there is potential for under- or overestimation of smoking
status, STEMI hospitalizations, and in-hospital outcomes
based on ICD-9-CM coding. NIS does not have medication
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data, so we had no information available on the adjunctive
antiplatelet and antithrombotic therapies used with PCI. Given
the lack of angiographic data, we were unable to account for
the severity of CAD or to assess the procedural success of
PCI. Last, outcomes in NIS are limited to in-hospital events,
and important data on long-term mortality in smokers versus
nonsmokers were not available.
Conclusion
In summary, in our large national unselected cohort of STEMI
patients undergoing pPCI, we found that smoking was
associated with lower risk-adjusted in-hospital mortality. We
also found that the association of smoking with reduced
mortality was driven largely by the association of smoking
with mortality in younger age groups. Age-stratified analyses
also found the smoker’s paradox, except in patients aged ≥90
years, suggesting that the average younger age of smokers
was not the sole explanation for the paradox. Although
weaker in magnitude, similar paradoxical associations of
smoking with lower risk-adjusted in-hospital mortality were
found in patients hospitalized with hip fractures or severe
sepsis during the same study period, implying that the
smoker’s paradox is related, at least in part, to continued
residual measured or unmeasured confounding. Whether
pathophysiological differences between smokers and non-
smokers with STEMI also account in part for this paradoxical
association needs to be established conclusively by future
studies.
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